Navigation Links
Physician to Implant the CATANIA(TM) Coronary Stent System With Polyzene(R)-F to Treat Chronic Total Occlusion During 'Live' Case at the Paris Cardiovascular Interventions Course (Francophone) 2008
Date:10/1/2008

Research Shows New Class of Stent Effective in Preventing Thrombosis,

Restenosis, and Reocclusion

PARIS, Oct. 1 /PRNewswire/ -- CeloNova BioSciences, Inc., today announced that Masahiko Ochiai MD, Associate Professor, Division of Cardiology, Yokohama Hospital, Kanagawa, Japan has selected the CATANIA(TM) Coronary Stent System featuring NanoThin Polyzene(R)-F for treating a patient with a chronic total occlusion (CTO) during a live case symposium at the Paris Cardiovascular Interventions (Francophone) Congress. The CATANIA(TM) Coronary Stent System carries a CE Mark and is currently available for sale in Europe.

(Photo: http://www.newscom.com/cgi-bin/prnh/20081001/CLW080-a )

(Logo: http://www.newscom.com/cgi-bin/prnh/20081001/CLW080LOGO-b )

Chronic total occlusion is defined as any artery where blood flow has been completely blocked for greater than 30 days. These types of lesions are exceptionally difficult to treat with percutaneous intervention (angioplasty) because of the challenges physicians face in crossing the lesion to move the catheter into place for proper stent deployment. The CATANIA(TM) Stent was selected for this live case because Polyzene(R)-F makes it highly lubricious and delivers low restenosis rates, excellent anti-thrombosis rates, and other clinical benefits that approach or, in some cases, may exceed those of DES, while addressing some of the significant ongoing concerns with current DES technology such as product cost, risk for thrombosis, and serious challenges associated with costly long-term dual anti-platelet therapy following treatment.

"The CATANIA(TM) Stent has superb pushability, trackability, and flexibility. You can feel that the Polyzene(R)-F surface is slicker than other stents," said Thierry Corcos, MD, Service de Cardiologie, Clinique Turin, Paris, France. "For the live case, we want to really test the CATANIA(TM) Stent's capabilities in a challenging anatomy, because of the clinical evidence that Polyzene(R)-F nanocoating prevents thrombosis, restenosis and reocclusion. Based on my experience, I believe the CATANIA(TM) Stent is an ideal choice for treating coronary artery disease, including chronic total occlusions."

The rapid-exchange, cobalt-chromium CATANIA(TM) Stent features a modified open-cell design and is available in 60 sizes in lengths from 8mm to 38mm and in diameters, from 2.0 to 4.0mm. The CATANIA(TM) Stent does not contain any drugs, off-loaded materials or biological substitutes. The proprietary nanothin, highly lubricious Polyzene(R)-F is a synthesized, inorganic, biocompatible polymer that is anti-thrombotic, anti-inflammatory, bacterial-resistant, and essentially cloaks the device's presence from the body to promote healthy endothelial cell growth without stimulating platelet activation. This unique combination of stent and surface treatment effectively creates a new and different class of stent that does not require long-term dual anti-platelet therapy.

"It is exceptionally gratifying that Dr. Corcos and Dr. Ochiai selected to showcase the abilities of the CATANIA(TM) Stent in such an important, and difficult-to-treat live case, because we design all of our products from the ground up using direct feedback from the physicians who use them," said Thomas A. Gordy, President and Chief Executive Officer, CeloNova BioSciences, Inc. "We are looking forward to presenting the CATANIA(TM) long-term, First-In-Man data on the world stage later this month during the Transcatheter Therapeutics (TCT) annual meeting in Washington, DC."

For more information about CeloNova BioSciences' products and Polyzene(R)-F technology, visit http://www.celonova.com .

About CeloNova BioSciences, Inc.

Headquartered in Newnan, near Atlanta, Georgia, CeloNova BioSciences, Inc., is a developer of novel medical devices that are then enhanced by one of the Company's proprietary materials, Polyzene(R)-F. Polyzene(R)-F is highly lubricious, anti-thrombotic, anti-inflammatory, and bacterial-resistant making it an ideal surface treatment for implanted medical devices. The Company's current products include its Embozene(TM) Color-Advanced Microspheres and the CATANIA(TM) Coronary Stent System with NanoThin Polyzene(R)-F. Other innovative devices are currently in the company's developmental pipeline. For more information, please visit http://www.celonova.com .

CONTACT: Robert J. Murphy

The Storch-Murphy Group

908-276-0777


'/>"/>
SOURCE CeloNova BioSciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Diageo Sponsors Medical Society of the State of New Yorks Physicians Training Program
2. Carrington and DaySpring Pharma Extend and Formalize Agreement for Distribution of Diabetic and Radiation Products Into Physician Market
3. Top Health Care Economists and Physician-Innovators Discuss Value of Medical Technology at AdvaMed 2007 Conference
4. Cynthia Haines, M.D., Named Managing Editor of Physicians Briefing News Wire
5. Young Physicians Demanding Advanced Laparoscopic Energy Instruments
6. FDA Approves Additional Dosage Strengths of Shires ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients
7. Physicians Practice, Loma Linda Partner to Improve Patient Care in Southern California
8. Physicians Reference Laboratory Announces New Diagnostic for Womens Health
9. Center for Molecular Medicine Partners with AviaraDx to Offer New Cancer Tests to Aid Physicians in Personalizing Treatment
10. Apieron, Inc. Announces FDA Clearance of the Insight(TM) eNO System to Assist Physicians with Patient Asthma Management
11. Hot Information for Physicians Treating Vasomotor Symptoms During the Menopausal Transition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... June 27, 2016 /PRNewswire/ - BIOREM Inc. (TSX-V: BRM) ("Biorem" ... by its major shareholders, Clean Technology Fund I, LP ... States based venture capital funds which together ... (on a fully diluted, as converted basis), that they ... their entire equity holdings in Biorem to TUS Holdings ...
(Date:6/27/2016)... ... June 27, 2016 , ... Parallel 6 , the ... today the Clinical Reach Virtual Patient Encounter CONSULT module which enables both ... physician and clinical trial team. , Using the CONSULT module, patients and physicians can ...
(Date:6/27/2016)... PHILADELPHIA , June 27, 2016  Liquid ... today announced the funding of a Sponsored Research ... study circulating tumor cells (CTCs) from cancer patients.  ... changes in CTC levels correlate with clinical outcomes ... therapies. These data will then be employed to ...
(Date:6/24/2016)... , June 24, 2016 Epic ... sensitively detects cancers susceptible to PARP inhibitors by ... tumor cells (CTCs). The new test has already ... therapeutics in multiple cancer types. Over ... DNA damage response pathways, including PARP, ATM, ATR, ...
Breaking Biology Technology:
(Date:6/16/2016)... 16, 2016 The global ... to reach USD 1.83 billion by 2024, according ... Inc. Technological proliferation and increasing demand in commercial ... to drive the market growth.      ... The development of advanced multimodal techniques for biometric ...
(Date:6/9/2016)... 9, 2016 Paris Police ... video security solution to ensure the safety of people and ... during the major tournament Teleste, an international technology ... services, announced today that its video security solution will be ... back up public safety across the country. The system roll-out ...
(Date:6/2/2016)... June 2, 2016 The Department of ... awarded the 44 million US Dollar project, for the ... Plates including Personalization, Enrolment, and IT Infrastructure , ... the production and implementation of Identity Management Solutions. Numerous renowned ... Decatur was selected for the most ...
Breaking Biology News(10 mins):